|
|
Survival benefit analysis of high flow oxygen therapy and standard oxygen therapy for patients with low immune function AHRF |
ZHANG Mingming1 ZHANG Qi1 SHU Qinqin1 WANG Wei2 ZHANG Xing2▲ |
1.Department of Critical Care Medicine, Shanghai General Hospital, Shanghai 200080, China;
2.Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai 200080, China |
|
|
Abstract Objective To investigate the survival benefit between high flow oxygen therapy and standard flow oxygen therapy for patients with low immune function AHRF. Methods From May 2017 to March 2019, a total of 72 cases in 3 intensive care units of Shanghai General Hospital and Shanghai Oriental Hospital were selected. According to the month of admision, the parity distribution method was adopted, they were divided into the high flow group and the standard flow group, with 36 cases in each group. The high-flow group was provided by oxygen therapy device and the standard flow group was provided by any device or combination of devices. All patients were observed for 28 d. The total mortality of 28 d, the number of deaths in and out of the ICU, the number of invasive ventilation, the number of acquired infections in the ICU, the length of stay in the ICU and the total length of stay in hospital were compared between the two groups. The risk ratio of randomized factor to mortality and cumulative invasive mechanical ventilation rate on 28 d were analyzed. Post-hoc analysis used a model and subset analysis of intubated patients. Results There were no statistically significant differences in terms of total death of 28 d, in and out of ICU death, invasive ventilation, and total hospital stay between the two groups (P > 0.05). The ICU acquired infection in the high flow group was lower than that in the standard flow group, and the length of stay in the ICU was shorter than that in the standard flow group, with statistically significant differences (P < 0.05). Randomization factors had no statistical significance on the mortality rate of 28 d (P > 0.05), and had a statistically significant effect on the cumulative invasive mechanical ventilation rate (P < 0.05). Conclusion Compared with standard flow oxygen therapy, high flow oxygen therapy does not significantly reduce the mortality rate and cumulative invasive mechanical ventilation rate in 28 d, but can improve the oxygenation index (PaO2/FIO2) in a short time, shorten the hospitalization time in ICU and reduce the rate of acquired infection in ICU.
|
|
|
|
|
[1] Harpaz R,Dahl RM,Dooling KL. Prevalence of immunosuppression among US adults,2013 [J]. JAMA,2016,316(23):2547-2548.
[2] 刘子希,朱继巧,马军,等.肝移植术后免疫抑制剂的减药方案临床研究进展[J].器官移植,2019,10(3):328-332.
[3] Azoulay E,Pickkers P,Soares M,et al. Acute hypoxemic respiratory failure in immunocompromised patients:the Efraim multinational prospective cohort study [J]. Intensive Care Med,2017,43(12):1808-1819.
[4] Lemiale V,Mokart D,Resche-Rigon M,et al. Effect of noninvasive ventilation vs oxygen therapy onmortality among immunocompromised patients with acute respiratory failure:a randomized clinicaltrial [J]. JAMA,2015,314(16):1711-1719.
[5] 朱蕾,胡莉娟.客观评价经鼻高流量氧疗[J].临床肺科杂志,2019,24(6):971-973.
[6] Frat JP,Ragot S,Girault C,et al. Effect of non-invasive oxygenation strategies inimmunocompromised patients with severe acuterespiratory failure:a post-hoc analysis of arandomised trial [J]. Lancet Respir Med,2016,4(8):646-652.
[7] Lemiale V,Resche-Rigon M,Mokart D,et al. High-flow nasal cannula oxygenation inimmunocompromised patients with acutehypoxemic respiratory failure:a Groupe deRec-herche Respiratoire en RéanimationOnco-Hématologique study [J]. Crit Care Med,2017,45(3):e274-e280.
[8] 刘华平,龚传明,屈磊,等.高流量氧疗与无创正压通气治疗COPD伴呼吸衰竭的比较[J].西南国防医药,2018, 28(12):1168-1170.
[9] Bellani G,Laffey JG,Pham T,et al. Noninvasive ventilation of patients with acute respiratory distress syndrome.Insights from the LUNG SAFE study [J]. Am J Respir Crit Care Med,2017,195(1):67-77.
[10] Ruan PK,Gray RJ. Analyses of cumulativeincidence functions via non-parametric multipleimputation [J]. Stat Med,2008,27(27):5709-5724.
[11] 罗琴,曹国磊,吐尔逊江·艾力,等.NHF治疗急性低氧性呼吸衰竭的临床疗效分析[J].新疆医科大学学报,2017, 40(5):591-595.
[12] 黄琳娜,李正东,夏金根,等.经鼻高流量氧疗在急性呼吸衰竭治疗中的应用[J].中华结核和呼吸杂志,2019, 42(1):41-44.
[13] 王睿,孙兵,李绪言,等.经鼻高流量氧疗治疗急性低氧性呼吸衰竭的临床疗效分析[J].中华结核和呼吸杂志,2017,40(2):155-157.
[14] 田野,黄絮,李敏,等.免疫抑制患者合并低氧性呼吸衰竭还需要无创通气吗?[J].中华重症医学电子杂志,2016, 2(4):254-257.
[15] Simon M,Wachs C,Braune S. High-flow nasal cannula versusbag-valve-mask for preoxygenation before intubation in subjects with hypoxemic respiratory failure [J]. Respir Care,2016,61(9):1160-1167.
[16] Hernández G,Vaquero C,González P,et al. Effect of postextubation high-flow nasal cannula vsconventional oxygen therapy on reintubation inlow-risk patients:a randomized clinical trial [J]. JAMA,2016,315(13):1354-1361.
[17] 张会云,高红梅,王兵,等.非HIV感染患者肺孢子菌肺炎合并急性呼吸衰竭16例诊疗分析[J].天津医药,2018,46(9):985-988.
[18] Brainard J,Scott BK,Sullivan BL,et al. Heated humidified high-flow nasal cannula oxygen after thoracic surgery-a randomized prospective clinical pilot trial [J]. J Crit Care,2017,40:225-228.
[19] Girardis M,Busani S,Damiani E,et al. Effect ofconservative vs conventional oxygen therapy onmortality among patients in an intensive care unit:the Oxygen-ICU randomized clinical trial [J]. JAMA,2016,316(15):1583-1589.
[20] Chu DK,Kim LH,Young PJ,et al. Mortality andmorbidity in acutely ill adults treated with liberalversus conservative oxygen therapy(IOTA):a systematic review and meta-analysis [J]. Lancet,2018,391(10 131):1693-1705. |
|
|
|